Trials / Completed
CompletedNCT02887417
Glioblastoma Platelet Activation Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 21 (actual)
- Sponsor
- University Medicine Greifswald · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Accepted
Summary
Glioblastoma face an increased risk of venous or arterial thromboembolism. Furthermore, the most frequent immune cells in glioblastoma are tumor associated macrophages, which find theirself in an anti-inflammatory (M2) phenotype. Increased conjugates between circulating platelets and monocytes reflect an pro-inflammatory status.
Detailed description
Glioblastoma face an increased risk of venous or arterial thromboembolism. Furthermore, the most frequent immune cells in glioblastoma are tumor associated macrophages, which find theirself in an anti-inflammatory (M2) phenotype. Increased conjugates between circulating platelets and monocytes reflect an pro-inflammatory status.
Conditions
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2016-10-01
- Completion
- 2016-12-01
- First posted
- 2016-09-02
- Last updated
- 2017-08-01
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02887417. Inclusion in this directory is not an endorsement.